

August 14, 2017

To <b>Department of Corporate Services</b> BSE Limited P J Towers, Dalal Street Mumbai - 400 001, India Scrip Code - BSE: <b>524500</b>	To <b>Corporate Listing Department</b> National Stock Exchange of India Ltd Exchange Plaza, Plot No.C-1, G Block, BKC, Bandra (E), Mumbai 400 051 NSE: <b>KILITCH</b>
--	--

Respected Sir/Madam,

**Sub: OUTCOME OF THE BOARD MEETING HELD ON MONDAY, AUGUST 14, 2017.**

With the reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e. Monday, August 14, 2017, for which intimation was already given to you, the Board of Directors has:

- Taken on record the Unaudited (Provisional) Financial Results of the Company for the Quarter ended June 30, 2017 along with the Limited Review Report as submitted by the Statutory Auditors of the Company;
- Appointed Mr. Deep Shukla, Practicing Company Secretary as a Scrutinizer to conduct the entire voting Process and voting done through physical ballot paper at the 25<sup>th</sup> AGM of the Company [including e-voting] and to submit the Report for declaration of the results thereof.
- Approved the Directors Report and the Corporate governance Report along with all relevant annexure thereof for the financial year ended 31.03.2017.
- Authorized Mr. Mukund Mehta, Managing Director of the Company, to oversee the entire E-voting process at the 25<sup>th</sup> AGM of the Company;

**Other Matter :**

- Appointed M/s. Deep Shukla & Associates, Company Secretaries as the Secretarial Auditor of the Company to issue Secretarial Audit report for the financial year ended 31.03.2018.

Further, the matters related to approval of the Notice of AGM, finalization of dates of book closure for the purpose of AGM and finalization of the date, time and venue for convening 25<sup>th</sup> AGM are postponed and shall be decided in the forthcoming board meeting, the intimation of which shall be forwarded to your esteemed exchange within stipulated time.


The meeting was commenced at 4:00 p.m. and concluded at 7:30 p.m. Please take the same in your records and do the needful.

Kindly find the same in order and acknowledge the receipt of the same.

Thanking You,

Yours faithfully,

**For: KILITCH DRUGS (INDIA) LIMITED**

  
**Mukund Mehta**  
DIN: 00147876  
**Managing Director**

Encl:a/a





**A. M. GHELANI & COMPANY**  
**CHARTERED ACCOUNTANTS**

224, Champaklal Industrial Estate  
Sion-Koliwada Road, Sion (East),  
Mumbai - 400 022.  
Tel : 2402 4909 / 8739  
Fax : 2407 1138  
E-mail : [amghelaniandco@gmail.com](mailto:amghelaniandco@gmail.com)

**AJIT M. GHELANI**  
B.Com (Hons), F.C.A., GRAD. C.W.A.

**CHINTAN A. GHELANI**  
B.Com (Hons), F.C.A., C.S

To,  
The Board of Directors  
Kilitch Drugs (India) Limited

**LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2017**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Kilitch Drugs (India) Limited for the Quarter ended June 30, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A. M. Ghelani & Company**


Chartered Accountants

FRN: 103173W

  
Chintan Ghelani

Partner

Membership No.: 104391



Place : Mumbai

Dated : 14 AUG 2017

**Encl: Unaudited financial results for quarter ended 30<sup>th</sup> June, 2017 of Kilitch Drugs (India) Limited.**



# KILITCH DRUGS (INDIA) LIMITED



## STATEMENT OF UNAUDITED FINANCIAL RESULTS

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701  
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com  
 CIN. L24239MH1992PLC066718

### Statement of Standalone Unaudited Financial Results for the Quarter ended June 30,2017

Rs. In Lacs

Sr. No.	Particulars	Three Months Ended	
		30-06-2017	30-06-2016
		Unaudited	Unaudited
1	Income from operations		
	Net Sales/ Income from operations(Inclusive of Excise duty)	669.47	690.07
	Other operating income	6.35	2.08
	<b>Total Income from Operations (Net)</b>	<b>675.82</b>	<b>692.13</b>
2	Expenses		
	(a) Cost of materials consumed	351.42	342.07
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(42.36)	(9.59)
	(c) Employee Benefit Expenses	99.86	72.59
	(d) Depreciation and Amortisation Expenses	28.04	41.19
	(e) Export Product Registration/Commission	31.34	36.84
	(f) Other Expenses	249.49	322.25
	<b>Total Expenses</b>	<b>717.79</b>	<b>805.35</b>
3	Loss from operations before Other Income, Finance Costs and Exceptional items (1-2)	(41.97)	(113.22)
4	Other Income	20.66	23.43
5	Loss from ordinary activities before finance cost and exceptional items (3+4)	(21.31)	(89.79)
6	Finance Costs	0.00	0.00
7	Loss from ordinary activities after finance costs but before exceptional items (5-6)	(21.31)	(89.79)
8	Exceptional Items	0.00	0.00
9	Loss from ordinary activities before tax (7+8)	(21.31)	(89.79)
10	Tax Expenses		
	Current Tax	0.00	0.00
	Deferred Tax	(9.75)	(9.69)
	Tax Adjustments of Earlier years	0.00	0.00
11	<b>Net Loss for the Quarter (9-10)</b>	<b>(11.56)</b>	<b>(80.10)</b>
12	Other Comprehensive Income (OCI) (net of tax expenses)	62.12	77.85
13	<b>Total Comprehensive Income for the Quarter (11+12)</b>	<b>50.56</b>	<b>(2.25)</b>
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18
15.i	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):		
	(a) Basic	(0.09)	(0.61)
	(b) Diluted	(0.09)	(0.61)
15.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):		
	(a) Basic	(0.09)	(0.61)
	(b) Diluted	(0.09)	(0.61)





**Notes:**

1 The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 14-08-2017.

2 This statement has been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1st April 2017, the Company has for the first time adopted Ind AS with a transition date of 1st April 2016.

3 The financial results for the quarter ended 30th June 2016 are restated to comply with Ind AS. The statement does not include Ind AS compliant results for the preceding quarter and previous year ended 31st March 2017 as the same are not mandatory as per SEBI's circular dated 5th July 2016.

4 The Ind AS compliant figures of the corresponding quarter of the previous year have not been subjected to a limited review or an audit. However, the Management has exercised necessary due diligence to ensure that such financial results provide a true and fair view.


5 The reconciliation of net profit/loss for the quarter ended June 30, 2016 reported under Indian GAAP (previous GAAP) to Total Comprehensive Income in accordance with Ind AS is as under :

(Rs. In Lacs)	
Particulars	Quarter ended 30.06.16
Net Loss for the Quarter as per Indian GAAP	(71.20)
Add/ (Less) : Adjustments for GAAP Differences	
Effect of Fair Valuation of Investments as per Ind AS 109	5.49
Expected Credit Loss (ECL) Provision on trade Receivables	(20.82)
Deferred Tax	6.43
Net Profit As per Ind AS	(80.10)
Other Comprehensive Income (after taxes)	
Effect of Fair Valuation of Investments through OCI as per Ind AS 109	77.85
Total Comprehensive Income (after taxes) as per Ind AS	(2.25)


6 The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

7 The Company has operated only in one reportable segment i.e. Pharmaceuticals.

Place : 14th August, 2017  
Date: Mumbai



For and on behalf of  
Board

  
Mukund P. Mehta  
Managing Director